We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Rachna Shroff

Rachna T. Shroff MD, MS

Chief, GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, Arizona

Dr. Rachna Shroff is an Associate Professor of Medicine and Chief of GI Medical Oncology at the University of Arizona Cancer Center (UACC). She also serves as the Director of UACC’s Clinical Trials Office and as the Vice Chair of Clinical Research for the Department of Medicine. She came to UACC from MD Anderson Cancer Center in Houston, TX where she was on faculty from 2010-2018 after completing her medical oncology fellowship there.

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak and national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and numerous peer-reviewed publications in this area.

 

Disclosures

Dr. Shroff discloses the following:
  • Research: Merck, Exelixis, Taiho, Rafael Pharmaceuticals, QED
  • Advisory Board: Merck, Exelixis, Incyte, Debio, QED, Astra Zeneca, Clovis

Recent Contributions to PracticeUpdate:

  1. Nivolumab for Advanced Refractory Biliary Tract Cancer